Upadacitinib tartrate
- Product NameUpadacitinib tartrate
- CAS1607431-21-9
- CBNumberCB83121346
- MFC21H25F3N6O7
- MW530.46
- EINECS-0
- MOL File1607431-21-9.mol
- MSDS FileSDS
Upadacitinib tartrate Price
| Product number | Packaging | Price | Product description | Buy |
|---|---|---|---|---|
| aablocks AA003AOS | 25mg | $475 | 1-Pyrrolidinecarboxamide, 3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(,2,2-trifluoroethyl)-,(3S,4R)-,(2R,3R)-2,3-dihydroxybutanedioate, hydrate (1:1:4) ≥98% |
Buy |
| aablocks AA003AOS | 50mg | $663 | 1-Pyrrolidinecarboxamide, 3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(,2,2-trifluoroethyl)-,(3S,4R)-,(2R,3R)-2,3-dihydroxybutanedioate, hydrate (1:1:4) ≥98% |
Buy |
| aablocks AA003AOS | 100mg | $1000 | 1-Pyrrolidinecarboxamide, 3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(,2,2-trifluoroethyl)-,(3S,4R)-,(2R,3R)-2,3-dihydroxybutanedioate, hydrate (1:1:4) ≥98% |
Buy |
| aablocks AA003AOS | 250mg | $1700 | 1-Pyrrolidinecarboxamide, 3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(,2,2-trifluoroethyl)-,(3S,4R)-,(2R,3R)-2,3-dihydroxybutanedioate, hydrate (1:1:4) ≥98% |
Buy |
| aablocks AA003AOS | 500mg | $2375 | 1-Pyrrolidinecarboxamide, 3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(,2,2-trifluoroethyl)-,(3S,4R)-,(2R,3R)-2,3-dihydroxybutanedioate, hydrate (1:1:4) ≥98% |
Buy |
Upadacitinib tartrate Chemical Properties,Usage,Production
Uses
Upadacitinib (ABT-494) tartrate tetrahydrate is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC50=43 nM). Upadacitinib tartrate tetrahydrate displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib tartrate tetrahydrate can be used for several autoimmune disorders research[1][2].in vivo
Upadacitinib (0.1-10 mg/kg; oral gavage; twice a day for 10 days) tartrate tetrahydrate demonstrates efficacy in rat arthritis models[3].
| Animal Model: | Female Lewis rats (Rat adjuvant-induced arthritis model)[3] |
| Dosage: | 0.1, 0.3, 1, 3, 10 mg/kg |
| Administration: | Oral gavage; twice a day for 10 days |
| Result: | Inhibited disease pathology in rat adjuvant induced arthritis. |
IC 50
JAK1: 0.043 μM (IC50); JAK2: 0.2 μM (IC50); JAK3: 2.3 μM (IC50); Tyk2: 4.7 μM (IC50)References
[1] Nakayamada S, et al. Recent Progress in JAK Inhibitors for the Treatment of Rheumatoid Arthritis. BioDrugs. 2016 Oct;30(5):407-419. DOI:10.1007/s40259-016-0190-5[2] J. Voss, et al. THU0127 Pharmacodynamics of A Novel JAK1 Selective Inhibitor in Rat Arthritis and Anemia Models and in Healthy Human Subjects. doi 10.1136/annrheumdis-2014-eular.3823.
[3] Parmentier JM, et al. In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatol. 2018 Aug 28;2:23. DOI:10.1186/s41927-018-0031-x
Preparation Products And Raw materials
Upadacitinib tartrate Suppliers
Global(14)Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| 021-20908456 | sales@BioChemBest.com | China | 5994 | 61 | |
| 177-54423994 17754423994 |
2853530910@QQ.com | China | 8000 | 62 | |
| 13006575422@163.com | China | 6346 | 58 | ||
| 021-58111628 15800915896 |
sales@twochem.com | China | 1782 | 58 | |
| 021-54338626 18017892860 |
sales@tubepharm.com | China | 2709 | 58 | |
| 18081075745 | chemflowtech@sina.com | China | 1883 | 58 | |
| meitaochem@126.com | meitaochem@126.com | China | 19086 | 58 | |
| +1-708-310-1919 +1-13798911105 |
sales@invivochem.cn | United States | 6377 | 58 | |
| 15347293736 | 2853117764@yongstandards.com | China | 9975 | 58 | |
| 13549236410 | sales@invivochem.cn | China | 6744 | 58 |
1607431-21-9, Upadacitinib tartrateRelated Search
PROMPT×
PROMPT
The WhatsApp is temporarily not supported in mainland China
The WhatsApp is temporarily not supported in mainland China
Cancel
Determine